GEN1E Lifesciences Inc.
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
0
Ending by 2030
May 2041
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Sep 12, 2027The maintenance fee for P38ALPHA Mitogen-Activated Protein Kinase Inhibitors (US 11,926,635) comes due Sep 12, 2027. Unpaid by Mar 13, 2028, it lapses early.
- 1 fee due Nov 7, 2027The maintenance fee for Substituted Naphthyl P38ALPHA Mitogen-Activated Protein Kinase Inhibitors (US 11,976,049) comes due Nov 7, 2027. Unpaid by May 8, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 22, 2026
- Oct 6 US 12,753,184 P38ALPHA Mitogen-Activated Protein Kinase Inhibitors
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,286,260 | P38ALPHA Mitogen-Activated Protein Kinase Inhibitors In force · High confidence | In force | High confidence | |
| US 11,440,918 | P38ALPHA Mitogen-Activated Protein Kinase Inhibitors In force · High confidence | In force | High confidence | |
| US 11,926,635 | P38ALPHA Mitogen-Activated Protein Kinase Inhibitors In force · High confidence | In force | High confidence | |
| US 12,753,184 | P38ALPHA Mitogen-Activated Protein Kinase Inhibitors In force · Medium confidence | In force | Medium confidence | |
| US 11,390,581 | Crystalline 5-(DIMETHYLAMINO)-N-(4-(MORPHOLINOMETHYL)PHENYL)NAPHTHALENE-1-Sulfonamide Di-Hydrochloride Di-Hydrate In force · High confidence | In force | High confidence | |
| US 12,269,792 | Crystalline 5-(DIMETHYLAMINO)-N-(4-(MORPHOLINOMETHYL)PHENYL)NAPHTHALENE-1-Sulfonamide Di-Hydrochloride Di-Hydrate In force · High confidence | In force | High confidence | |
| US 11,555,020 | Substituted Naphthyl P38ALPHA Mitogen-Activated Protein Kinase Inhibitors In force · High confidence | In force | High confidence | |
| US 11,976,049 | Substituted Naphthyl P38ALPHA Mitogen-Activated Protein Kinase Inhibitors In force · High confidence | In force | High confidence | |
| US 12,331,024 | Substituted Naphthyl P38ALPHA Mitogen-Activated Protein Kinase Inhibitors In force · High confidence | In force | High confidence | |
| US 12,116,353 | Crystalline CHLORO-N-(4-(MORPHOLINOMETHYL)PHENYL)BENZAMIDE and Crystalline Hydrochloride Salt In force · High confidence | In force | High confidence |
Also on record, not counted in the 11: 1 patent in force now held by others. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
4 pending · 1 abandoned